scholarly journals The Continuing Value of CD4 Cell Count Monitoring for Differential HIV Care and Surveillance

10.2196/11136 ◽  
2019 ◽  
Vol 5 (1) ◽  
pp. e11136 ◽  
Author(s):  
Brian Rice ◽  
Andrew Boulle ◽  
Sandra Schwarcz ◽  
Amir Shroufi ◽  
George Rutherford ◽  
...  
Keyword(s):  
Hiv Care ◽  
2013 ◽  
Vol 57 (7) ◽  
pp. 1027-1037 ◽  
Author(s):  
C. R. Lesko ◽  
S. R. Cole ◽  
A. Zinski ◽  
C. Poole ◽  
M. J. Mugavero

PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0162085 ◽  
Author(s):  
Susie Hoffman ◽  
Theresa M. Exner ◽  
Naomi Lince-Deroche ◽  
Cheng-Shiun Leu ◽  
Jessica L. Phillip ◽  
...  

2016 ◽  
Vol 28 (8) ◽  
pp. 814-821 ◽  
Author(s):  
Sarah O’Connell ◽  
Julia Enkelmann ◽  
Corinna Sadlier ◽  
Colm Bergin

Delayed diagnosis of HIV infection has negative clinical, economic and public health implications. The study primary aim was to identify factors associated with late HIV presentation (Late Presenters [LPS], CD4 cell count < 350 cells/mm3). A secondary aim was to identify changing trends of late HIV presentation from 2002 to 2014 at our centre. A retrospective cohort study was performed. Demographic data and CD4 cell count of new HIV diagnoses presenting to our ambulatory HIV service over four time-periods from 2002 to 2014 were recorded. Proportion of LPS and factors associated with late presentation were compared using Graphpad Instat. In 2014, of 231 new patients attending for HIV care, 75 (32.6%) were late presenters versus 146 (66.4%) in 2002. This indicates a decreasing proportion of LPS from 2002 to 2014. However, the proportion of those with CD4 cell counts <200 on presentation at these two time intervals remain unchanged. The overall proportion of male LPS has increased over time and the proportion of LPS in the men who have sex with men (MSM) cohort has decreased over time, reflecting increased frequency of both HIV testing and diagnoses in MSM in recent years. The proportion of heterosexual LPS has not changed significantly in the same time period and LPS were older in 2014 versus 2002. The proportion of LPS defined by CD4 cell count remains higher than is justifiable in an era of increased HIV testing and awareness. Further targets for HIV testing to decrease rates of LPS include non-traditional risk groups including heterosexual and older patient cohorts. LPS rates are lower than rates found internationally, and it is possible that consensus definition of LPS needs to be revised.


2019 ◽  
Vol 30 (13) ◽  
pp. 1257-1264 ◽  
Author(s):  
Nima Ghalehkhani ◽  
Behnam Farhoudi ◽  
Mohammad Mehdi Gouya ◽  
Hamid Sharifi ◽  
SeyedAhmad SeyedAlinaghi ◽  
...  

The study assessed the HIV treatment cascade of people living with HIV (PLWH) in Iran and the reasons for gaps in HIV services in 2014. We did the cascade analysis using the WHO HIV test–treat–retain cascade analysis tool (2014). To measure the gaps, we checked the records for all PLWH reported to the national HIV surveillance till September 2014 to define how many were alive, linked to HIV care, assessed for CD4 cell count, started antiretroviral therapy (ART), and reported to be alive up to five years after ART. To assess the reasons for gaps in the cascade, we ran desk review, four focus group discussions and 51 in-depth interviews with key informants including PLWH. Spectrum model estimated 75,700 PLWH in Iran, of whom only 22,647 people (%30) were diagnosed. Of those who were diagnosed with HIV, 16,266 people (%72) had enrolled in HIV care. About 13% of all PLWH were retained in HIV care and only 9% (6745 people) had ever been tested for CD4 cell count. Only 8% (6018 people) of all PLWH had received ART by September 2014. We found the biggest gap in the HIV treatment cascade to be HIV diagnosis as only 30% of PLWH have been diagnosed. Innovative strategies to improve HIV testing, particularly those that work best for key populations, are critical to reach the 90–90-90 targets.


2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Nadine Mayasi Ngongo ◽  
Hippolyte Situakibanza Nani-Tuma ◽  
Marcel Mbula Mambimbi ◽  
Murielle Longokolo Mashi ◽  
Ben Bepouka Izizag ◽  
...  

Abstract Introduction Late presentation for HIV care is a well-described issue for the success of ART outcomes and the cause of higher morbidity, mortality and further transmission. Monitoring the level of late presentation and understanding the factors associated with it would help to tailor screening and information strategies for better efficiency. We performed a retrospective cohort study in Kinshasa, the capital of the DRC. The studied population included HIV-positive adults newly enrolled in HIV care between January 2006 and June 2020 at 25 HIV urban care facilities. Patient information collected at presentation for HIV care included age, sex, WHO clinical stage and screening context. We used 2 definitions of late presentation: the WHO definition of advanced HIV disease (WHO stage 3/4 or CD4 cell count < 200 cells/mm3) and a more inclusive definition (WHO stage 3/4 or CD4 cell count < 350 cells/mm3). Results A total of 10,137 HIV-infected individuals were included in the analysis. The median age was 40 years; 68% were female. A total of 45.9% or 47.5% of the patients were late presenters, depending on the definition used. The percentage of patients with late presentation (defined as WHO stage 3/4 or CD4 cell count < 350 cells/mm3) decreased during recent years, from 70.7% in 2013 to 46.5% in 2017 and 23.4% in 2020. Age was associated with a significantly higher risk of LP (p < 0.0001). We did not observe any impact of sex. Conclusions The frequency of late presentation for care is decreasing in Kinshasa, DRC. Efforts have to be continued. In particular, the issue of late diagnosis in older individuals should be addressed.


2018 ◽  
Author(s):  
Brian Rice ◽  
Andrew Boulle ◽  
Sandra Schwarcz ◽  
Amir Shroufi ◽  
George Rutherford ◽  
...  

UNSTRUCTURED The move toward universal provision of antiretroviral therapy and the expansion of HIV viral load monitoring call into question the ongoing value of CD4 cell count testing and monitoring. We highlight the role CD4 monitoring continues to have in guiding clinical decisions and measuring and evaluating the epidemiology of HIV. To end the HIV/AIDS epidemic, we require strategic information, which includes CD4 cell counts, to make informed clinical decisions and effectively monitor key surveillance indicators.


2018 ◽  
Vol 29 (11) ◽  
pp. 1098-1105 ◽  
Author(s):  
Hartmut B Krentz ◽  
M John Gill

Individuals diagnosed with HIV before 1996 had poor prognoses. Few HIV care centers can track patients continuously from the 1980s to present. We determined the sociodemographic, clinical, and health care utilization characteristics of patients diagnosed and followed for >20 years (i.e. long-term HIV/AIDS survivors) to understand what factors contributed to survival. All HIV-positive patients diagnosed before 1996 were categorized as active, moved/lost, or died as of 1 January 2016. Baseline sociodemographic, clinical characteristics, antiretroviral therapy (ART) usage, retention, HIV care costs, and health status were analyzed. Of 876 patients, 49.5% died, 30.3% moved or left, 20.3% remained active in care for a median of 23.4 years. At diagnosis, continuously-followed patients were younger with a higher CD4 cell count, attended regular clinic visits at higher frequencies, and had received more ART than patients who moved or died. As of 1 January 2016, their median age was 57 years (interquartile range 53–62), 15% were aged >65 years, median CD4 cell count was 591 cells/mm3 (475–863) with 68% >500 cells/mm3. Sixty-two percent remained employed. The total cost of HIV care was $32,251,030 (Cdn$); median cost per patient per year $15,418 ($13,697–$18,392). Individuals diagnosed prior to 1996 benefited from early diagnosis and engagement to care, regular follow-ups, and timely initiation of ART, strongly supporting the modern guidelines of care.


2019 ◽  
Vol 30 (9) ◽  
pp. 853-860
Author(s):  
Andrea M Pallotta ◽  
Sana A Pirzada ◽  
Rabin K Shrestha ◽  
Belinda Yen-Lieberman ◽  
Leonard H Calabrese ◽  
...  

Universal HIV screening and treatment initiation of HIV-positive persons are well-established standards. However, late presentation to care is a barrier to early antiretroviral therapy (ART) and prevention of HIV transmission. We sought to determine the immunodeficiency at presentation to care and characterize the initiation and response to ART among HIV-positive persons over 2003–2013 in our urban HIV clinical practice at the Cleveland Clinic. Using a retrospective cohort study design, we assessed the CD4 cell count of HIV-positive patients at entry into care for each year and evaluated the trend over time. For patients who initiated treatment, we assessed the pretreatment CD4 cell count, consistency of timing and regimen with US treatment guidelines, and HIV RNA level at one-year and last follow-up visits. Regression analyses were used to determine predictors of study outcomes. We found that the cohort (N = 452) median CD4 cell count at presentation to care was 297 cells/mm3 (inter-quartile range: 104–479 cells/mm3), without any significant change over time (P = 0.62), and with 37% and 21% of presentations being late and advanced, respectively. Guideline-consistency (85%–100%) and regimen-consistency (41%–100%) were moderate to high and improved over time. Virologic suppression (<400 copies/ml) at one year and last follow-up was high (79% and 92%) and associated with regimen selection and durability. We conclude that CD4 cell count at first presentation to HIV care remained less than 350 cells/mm3 for 11 years in our clinical practice, despite advances in HIV testing and treatment guidelines. Early diagnosis and linkage to care and treatment are critical for ending the HIV epidemic.


Sign in / Sign up

Export Citation Format

Share Document